<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="193443">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00573833</url>
  </required_header>
  <id_info>
    <org_study_id>07-120</org_study_id>
    <secondary_id>MSKCC-07120</secondary_id>
    <nct_id>NCT00573833</nct_id>
  </id_info>
  <brief_title>Internal Radiation Therapy in Treating Patients With Prostate Cancer</brief_title>
  <official_title>A Pilot Study of High Dose Rate Brachytherapy as Definitive Management for Intermediate Risk Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Internal radiation therapy uses radioactive material placed directly into or near
      a tumor to kill tumor cells.

      PURPOSE: This clinical trial is studying the side effects and how well internal radiation
      therapy works in treating patients with prostate cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  To assess the feasibility of high-dose rate (HDR) brachytherapy (without the use of
           external-beam radiotherapy) as definitive treatment for patients with intermediate-risk
           prostate cancer.

        -  To assess acceptable toxicity, defined as treatment related toxicity (urinary and
           rectal), no worse than that seen by patients treated with conventional therapy (grade 3
           urinary toxicity &lt; 10% and grade 3 rectal toxicity &lt; 10%).

      Secondary

        -  To achieve adequate dosimetric coverage of the prostate comparable to current
           standards.

        -  To assess the effect of treatment on sexual function.

      OUTLINE: Patients undergo 4 high-dose rate brachytherapy treatments over 2 days.

      Patients complete bladder, bowel, sexual function, and quality of life questionnaires,
      including the International Index of Erectile Function (IIEF) questionnaire, the
      International Prostate Symptom Score Index (IPSS), and the MSKCC Prostate Quality of Life
      questionnaire at baseline and then at every follow-up visit.

      After completion of study treatment, patients are followed every 3 months for 1 year.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility</measure>
    <time_frame>At scheduled 3 month intervals for one year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Toxicity as assessed by NCI CTC and the International Prostate Symptom Score Index</measure>
    <time_frame>Within 90 days of treatment (early toxicities) or after 90 days (late toxicities)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Quality of life as measured by the MSKCC Prostate Quality of Life questionnaire</measure>
    <time_frame>At scheduled 3 month intervals for one year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Sexual function as measured by the International Index of Erectile Function (IIEF)</measure>
    <time_frame>At scheduled 3 month intervals for one year</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>HDR Brachytherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>9.5 Gy HDR Brachytherapy for 4 fractions given over 2 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>questionnaire administration</intervention_name>
    <arm_group_label>HDR Brachytherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>quality-of-life assessment</intervention_name>
    <arm_group_label>HDR Brachytherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>brachytherapy</intervention_name>
    <arm_group_label>HDR Brachytherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

        Inclusion criteria:

          -  Intermediate-risk adenocarcinoma of the prostate, defined by 1of the following
             criteria:

               -  PSA 10-20 ng/mL

               -  Gleason score ≥ 7

               -  Stage ≥ T2b AND &lt; T3

          -  Less than 20% risk of seminal vesicle involvement or lymph node involved based upon
             the Kattan nomogram (pre-treatment risk with IMRT)

          -  Prostate size &lt; 60 cc by MRI or CT imaging

          -  International Prostate Symptom Score Index ≤ 15

        Exclusion criteria:

          -  Evidence of definitive extracapsular extension/seminal vesicle invasion or pelvic
             adenopathy by MRI (endorectal coil) and DRE (digital rectal examination)

               -  Suspected extracapsular disease will not be considered an exclusion criteria

          -  PSA &gt; 20 ng/mL

          -  Presence of distant metastases

        PATIENT CHARACTERISTICS:

          -  WBC ≥ 3,500/mm³

          -  Platelet count ≥ 75,000/mm³

          -  Hemoglobin ≥ 10 g/dL

          -  Creatinine ≤ 1.5 mg/dL

          -  Liver function tests ≤ 1.5 times normal

          -  INR ≤ 2.5

          -  Able to complete quality of life questionnaires

          -  Able to give informed consent

          -  No active perineal infections

          -  No history of urethral stricture

          -  No prior history of pelvic malignancy

          -  No prior history of lymphoma disease, ulcerative colitis, or anal fissures

          -  No contraindications to general anesthesia

          -  No pacemaker

        PRIOR CONCURRENT THERAPY:

          -  No prior transurethral resection of the prostate

          -  No prior pelvic radiotherapy

          -  No prior treatment for prostate cancer except for hormone therapy
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Josh Yamada, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael J. Zelefsky, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sherri M. Donat, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marco Zaider, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <lastchanged_date>September 11, 2014</lastchanged_date>
  <firstreceived_date>December 13, 2007</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adenocarcinoma of the prostate</keyword>
  <keyword>stage IIB prostate cancer</keyword>
  <keyword>stage IIA prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
